Emgality 300 mg: First and only CGRP antagonist antibody proven to treat adult patients with episodic cluster headache1,2

Cluster headache patient Frank looking forward smiling

Meet Franka

  • 1 TO 4 ATTACKS PER DAY during active periods that last 7 weeks, followed by periods (≥3 months) of remission
  • Tends to seek medical care DURING ACTIVE CLUSTER PERIODS
  • May have already TRIED OTHER TREATMENT OPTIONS

aHypothetical patient profile with episodic cluster headache.

CGRP=calcitonin gene-related peptide.

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the treatment of episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

References

  1. Emgality. Prescribing Information. Lilly USA, LLC.
  2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache